joimax Receives 510(k) Clearance for Percusys Pedicle Screw-Rod System

IRVINE, Calif., March 4, 2015 (GLOBE NEWSWIRE) — The German company joimax®, developer of technologies and training methods for minimally invasive endoscopic spinal surgery, today announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market its Percusys® percutaneous pedicle screw-rod system.

The patented Percusys system is a multi-functional implant for use during spinal stabilization procedures. Its unique screw and instrument design enables a safer and more effective surgical technique with minimal steps for the surgeon. The single, small instrument set allows flexibility to perform surgery through a percutaneous, minimally invasive or open approach.

“During development, the main focus was on the ease-of-use of the system,” says Dr. Frank Hassel, specialist for spine surgery from Freiburg, Germany, who was instrumental to the Percusys development. “The idea was to reduce the complexity in instrumentation and simplify stabilization procedures to minimize the potential damage of soft tissues and improve overall patient outcomes.”

Percusys implants comprise single packaged, sterile, and pre-assembled pedicle screws with lengthening shaft and set-screw. All screws are color coded according to their diameter, cannulated, fenestrated, self-cutting and self-drilling. Each surgical step is carried out using the lengthening shaft, which is tightly connected to the tulip. The assembly allows for direct manipulation and does not require additional instrumentation. Shearing off the lengthening shaft can be done by a 360-degree rotation of the shaft breaker.

Percusyscan be usedin combination with the joimax® EndoLIF® O-Cage. “This offers an optimal solution for minimally invasive, endoscopic-assisted access to the intervertebral disc,” says Wolfgang Ries, CEO and founder of joimax. “Percusys® represents the next logical step in the development of endoscopic surgery and further strengthens the joimax position as an expert in this special market segment.”

joimax® Announces Executive Appointments Among Record-Breaking Sales for 2022

KARLSRUHE, Germany – (BUSINESS WIRE) – joimax®, the German-based market leader in technologies and training methods for full-endoscopic and minimally invasive spinal surgery, has appointed Mr. Maximilian Ries and Mr. Anthony Troncale to new executive positions, effective January 1. The announcement comes among record-breaking sales across Europe, Asia, and the United States in 2022.

Maximilian Ries

Ries took on the newly created role of Executive Vice President, Business Development and Operations at joimax®. In this position, based in Germany, he will be responsible for scaling global operations to ensure joimax® continues its exponential growth. Formerly the General Manager, for the past six of his 13-year tenure with joimax®, Ries built out the United States and Latin American markets.

Tony Troncale

Troncale was promoted to General Manager; he was formerly Vice President of Marketing and Business Development at joimax® Inc. Over the past two years, Troncale, in addition to increasing his responsibilities, successfully capitalized on the significant interest in endoscopic techniques to expand US sales operations. He joined joimax® in 2021 bringing 20-years of experience in the spinal device industry where he served in sales and marketing leadership roles at Stryker, K2M, and Synthes Spine. Contributing to the global organization’s continuous strong sales growth was the launch of a new surgical access system, “Tessys® Trans SAP” and the global expansion of the ESPINEA® Education Academy.

Wolfgang Ries

“I am extremely pleased with our 2022 global performance and the significant interest in endoscopic spine surgery,” stated joimax® Founder and CEO Wolfgang Ries. “With Max and Tony in their new roles, our market-leading endoscopic spine technologies, and our anticipated launch of two more new surgical access systems later in 2023, we are well positioned for another very successful year.”